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Alcoholic hepatitis (AH) is a clinical manifestation on the spectrum of alcoholic liver diseases 
related to alcohol consumption. The mildest of these diseases is fatty liver, which can progress to 
AH and then lead to cirrhosis with continual alcohol use. Alcohol is the leading cause of liver 
disease in the world and the third most common cause of preventable death in the United States 
(1, 2). This goes to show that alcohol use is a major problem and the clinical diseases that arise 
from its use are extremely prevalent among hospitalized patients. Recently, there has been ample 
research into the pathophysiology, management, and treatment of AH in the hospitalized patient; 
however, the mainstay of treatment has not changed even though many theoretical options are 
being investigated. 
 
 
DEFINING AH 
 
AH is a clinical diagnosis that makes it 
difficult to come to an agreement on the 
signs and symptoms that define this 
condition. However, a common definition is 
a patient with a history of current, or 
previous, heavy alcohol use that develops 
jaundice with elevated serum aspartate 
aminotransferase (AST) (3). The term 
‘heavy alcohol use’ proves problematic to 
define, but for the clinical diagnosis patients 
should have been drinking for >6 months 
with <60 days of abstinence before the onset 
of jaundice (3). Other clinical features that 
are common, but not specific for AH, 
include: tender hepatomegaly, fever, ascites, 
and/or encephalopathy (4). With these 
common signs and symptoms, it is difficult 
to determine the underlying etiology of liver 
disease in the absence of alcohol use history. 
However, laboratory studies may be 
beneficial to elucidate the underlying 
etiology. In AH, the AST and alanine 
aminotransferase (ALT) levels are usually 2-
6 times the upper limit of normal with an 
AST/ALT ratio of greater than 2 (4). 
Patients may also have associated 
neutrophilia, hyperbilirubinemia, and 
coagulopathy due to synthetic liver 
dysfunction associated with AH (4). Most of 
these signs and symptoms are common 
among all liver diseases; however, it is the 
history of alcohol use that truly points to this 
diagnosis.  
 
PREVALENCE 
 
Since AH exists on a disease spectrum its 
exact prevalence is difficult to determine 
and many patients are completely 
asymptomatic. Further, it is common for 
physicians not to seek out this disease when 
the patient does not give any indication of 
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alcohol use or abuse. However, a recent 
study showed that alcohol-related 
hospitalizations has increased by 25% 
among 18-25 year-olds in the United States 
between 1999 and 2008 (5). Another study 
reported the prevalence of AH in a cohort of 
1604 alcoholics to be close to 20% based on 
liver biopsy data (6). To further illustrate the 
magnitude of AH, in one study using 
National Inpatient Sample data, AH 
accounted for 56,809 hospitalizations in the 
US in 2007; this was 0.71% of all 
hospitalizations (6). Thus, as alcohol 
becomes more available, especially among 
teenagers and young adults, the incidence of 
AH is expected to rise in the future.  
 
RISK FACTORS FOR DEVELOPMENT 
OF AH 
 
The risk of developing AH shares many 
similarities with development of alcoholic 
liver disease, and it is based on many 
environmental and genetic risk factors that 
have not been fully elucidated to date. 
However, the strongest predisposing risk 
factor is alcohol use. In fact, a strong 
positive correlation between cumulative 
alcohol intake and degree of liver fibrosis 
has been widely reported in the literature 
(7). Interestingly, excessive alcohol use is 
not sufficient to promote alcoholic liver 
disease alone. There are other environmental 
and genetic factors at play because only 1 in 
5 heavy drinkers will develop AH and only 
1 in 4 will go on to develop liver cirrhosis 
(8). Since alcohol is a major risk factor for 
the development of AH, it is important to 
define how much alcohol is too much. 
Unfortunately, there is no consensus on the 
exact amount of alcohol that poses a risk for 
the development of AH; however, there is 
more agreement on the amount that can lead 
to liver cirrhosis. One study found that with 
an “above a risk ‘threshold’, of about three 
standard drinks per day, there is a steep 
dose-dependent increase in the relative risk 
of cirrhotic or non-cirrhotic liver disease” 
(9). Moreover, another study found that the 
risk of developing cirrhosis increases with 
ingestion of greater than 60-80 grams per 
day of alcohol for 10 years or longer in men 
and greater than 20 grams per day in women 
(10, 11).  These studies demonstrate that 
there is a dose-dependent relationship 
between alcohol consumption and the 
incidence of alcohol related sequelae. 
Further, it has also been shown that 
individuals that drink daily are at an 
increased risk of developing AH as 
compared to binge drinking (8). Finally, the 
risk of AH was higher in individuals who 
drink beer and spirits as compared to 
drinking wine (6).  
Besides the obvious detrimental 
effects of alcohol, there are many other risk 
factors for development of AH (table 1). 
Even though males are more commonly 
affected by AH, female gender is a widely-
accepted risk factor (12). Women are more 
prone to the effects of alcohol because 
women have decreased gastric alcohol 
dehydrogenase levels compared to men, 
women have a higher proportion of body fat, 
and women experience changes in 
gastrointestinal alcohol absorption related to 
estrogen fluctuations throughout the 
menstrual cycle (6, 12). Other risk factors 
are certainly at play in AH and these 
include: obesity, glucose derangements, and 
many genetic factors (13). In terms of 
genetics, the rates of alcoholic liver diseases 
are higher in African-American and 
Hispanic males compared to Caucasians and 
mortality rates are highest in Hispanic males 
(14). Interestingly, this difference cannot be 
explained by the amount of alcohol 
consumption since no significant difference 
exists among the groups (12). Age is also a 
commonly reported risk factor since AH is 
mostly seen in the 40-50-year-old age range 
(6).  
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A final risk factor that is currently 
being heavily studied in terms of 
management of AH is the extent of 
malnutrition. The degree of malnutrition 
plays a direct role in determining outcome 
and prognosis of patients with AH (15). 
Mortality increases in direct proportion to 
the extent of malnutrition and approaches 
80% in patients with severe malnutrition 
(15). There has also been a new focus on 
micronutrient abnormalities that commonly 
occur in AH. Alcohol may cause hepatic 
vitamin A depletion or depressed vitamin E 
levels which may aggravate and propel liver 
disease (16). Further, diets rich in 
polyunsaturated fats have also been shown 
to increase progression of alcohol-induced 
liver disease in animals (17). Thus, 
nutritional support in AH is an active area of 
research and investigators are trying to 
determine the best management strategies 
and discover how nutritional status affects 
long-term management. 
 
Table 1. Associated risk factors for AH 
 
1. Female Gender 
2. Race (African-American and Hispanic) 
3. Age (40-50-year-old age range) 
4. Malnutrition 
5. Obesity 
6. Dysglycemia 
 
PATHOPHYSIOLOGY OF 
ALCOHOLIC HEPATITIS  
 
Ethanol is oxidized by three metabolic 
pathways:  
1. Ethanol (EtOH)AcetaldehydeAcetate  
2. Cytochrome P450 2E1 
3. Catalase  
 
1. Ethanol (EtOH)  Acetaldehyde  
Acetate Pathway: 
Ethanol  Acetaldehyde  Acetate is the 
major oxidative pathway of alcohol 
metabolism in the liver, as 90% of ethanol is 
metabolized through this pathway. Ethanol 
is initially oxidized by alcohol 
dehydrogenase (ADH) to acetaldehyde in 
the hepatocyte (13). Acetaldehyde is a 
highly toxic molecule that can build up 
before it is metabolized to acetate by 
mitochondrial acetaldehyde dehydrogenase 
(ALDH) (18-20). 
This oxidation process involves an 
intermediate carrier of electrons, 
nicotinamide adenine dinucleotide (NAD
+
), 
which is reduced to form NADH. As a 
result, alcohol oxidation generates a highly 
reduced cytosolic environment in 
hepatocytes and hepatocytes become 
vulnerable to tissue injury by free radicles. 
 
 
 
2.  Cytochrome P450 2E1 Pathway: 
The cytochrome P450 system is also 
intimately involved in the metabolism of 
alcohol; more specifically the cytochrome 
P450 2E1 (CYP2E1) isoenzyme is involved 
(21). About 10% of ethanol oxidation occurs 
in the microsomal cytochrome P450 
CYP2E1.  CYP2E1 is upregulated in 
response to chronic alcohol intake which 
leads to an increased production of free 
radicals through oxidation of nicotinamide 
adenine dinucleotide phosphate (NADPH) to 
NADP
+
 (22).  
 
 
 
3.  Catalase Pathway: 
Catalase has a minor role in oxidation of 
ethanol. Located in peroxisomes, catalase is 
capable of oxidizing ethanol in vitro in the 
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presence of a hydrogen peroxide (H2O2) -
generating system, such as the enzyme 
complex NADPH oxidase or the enzyme 
xanthine oxidase.  
 
 
 
Consequences of Alcohol Metabolism:   
The damage to hepatocytes is caused by 
these inter-related pathways.  
 
A. Increase in the NADH/NAD+ ratio: 
Both, alcohol dehydrogenase and 
acetaldehyde dehydrogenase, cause a 
reduction of NAD
+
 to NADH (21). This 
leads to an increase in the NADH/NAD
+
 
ratio in the hepatocyte, which promotes 
lipogenesis and decreases gluconeogenesis 
and fatty acid oxidation (21). Increased 
lipogenesis in hepatocytes leads to fat 
accumulation (steatosis) throughout 
hepatocytes and liver parenchyma.  
 
B. Acetaldehyde adducts:  
Furthermore, the intermediate acetaldehyde 
can easily form adducts with hepatocyte 
proteins which can cause conformational 
changes and dysfunction in those proteins 
(22). Acetaldehyde also induces 
inflammation in hepatocytes by causing 
direct activation of transforming growth 
factor beta (TGF-). TGF- then goes on to 
induce fibrosis by activating hepatic stellate 
cells (23).  
 
C. Increased free radicals: 
CYP2E1 is upregulated in response to 
chronic alcohol intake which leads to 
increased production of free radicals through 
oxidation of NADPH to NADP
+ 
(22). The 
increased free radicals cause depletion of 
glutathione leading to more rapid adverse 
effects. Injury is induced by these free 
radicals by lipid peroxidation in cell and 
organelle membranes. The endoplasmic 
reticulum and mitochondria are especially 
affected ultimately leading to hepatocyte 
death (13).  
 
D. Hypoxia: 
NADH is a major byproduct of alcohol 
metabolism, which is later oxidized in 
mitochondria and generates metabolic water 
by binding molecular oxygen and protons. 
Hepatocytes, in close proximity to this 
chemical reaction, take up more oxygen, 
resulting in decreasing arterial oxygen 
supply to distally located cells. Thus, peri-
venular hepatocytes are first to have hypoxic 
damage due to alcohol consumption (24, 
25).  
In addition, ethanol directly activates 
Kuppfer cells resulting in increased 
consumption of oxygen. Activated Kuppfer 
cells release many stimulatory cytokines 
including prostaglandin E2, which increases 
the metabolic activity of hepatocytes. Many 
essential molecules are broken down and 
formed because of activation of chemical 
reactions requiring oxygen, resulting in 
worsening of hypoxia induced cell damage 
to hepatocytes (26). 
 
E. Alcohol induced gut permeability with 
endotoxemia and inflammatory 
cascade: 
Recent research on the effects of alcohol has 
elucidated its effect on the gut microbiome 
and the alteration in the delicate balance 
among pathogenic and commensal 
organisms (27). Alcohol disrupts the 
intestinal mucosal barrier and allows 
lipopolysaccharide (LPS) from gram-
negative bacteria to be absorbed more easily 
and enter the portal circulation (13). Once at 
the liver, the LPS can cause activation of 
Kupffer cells and a signaling cascade 
through Toll-Like-Receptor-4 (TLR4) (28). 
TLR4 activation leads to the production and 
secretion of pro-inflammatory cytokines 
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such as IL-1, IL-6, and tumor necrosis factor 
alpha (TNF-) (13). These cytokines have 
been shown to act on hepatocytes and 
surrounding hepatic structural cells to 
contribute to inflammatory and fibrogenic 
processes (13).  
 
DIAGNOSIS OF AH 
 
Even though AH is a clinical diagnosis and 
there is no universally accepted diagnostic 
criteria, the diagnosis in patients comes 
down to documentation of excess alcohol 
use and evidence of liver disease (29).  
 
History:  
Even with exam and laboratory findings 
suggestive of liver sequelae, alcohol abuse 
should be elucidated and documented to 
diagnose AH. The simplest way to do this is 
to talk to patients about previous and current 
alcohol use practices. Unfortunately, many 
patients are not forth-coming about their 
alcohol use, so certain screening practices 
have been developed to identify these 
patients. The CAGE questionnaire is a four-
question screening test that is widely used 
among practitioners to identify alcohol use 
in patients (30). A meta-analysis found the 
CAGE questionnaire to have a sensitivity 
and specificity of 0.71 and 0.95, respectively 
(30). The AUDIT questionnaire is also an 
acceptable alternative to screen for alcohol 
use disorders, but is more cumbersome to 
perform. The initial step in diagnosing AH is 
to screen patients for alcohol use by means 
of talking with them or administering 
screening questionnaires, which can initiate 
communication between patient and 
provider. 
 
Physical Finding: 
In terms of physical exam findings, patients 
may range from no exam findings to those 
seen in advanced liver disease. Further, 
physical exam features generally have low 
sensitivity, even for the detection of 
advanced liver disease or cirrhosis (10). 
However, some exam findings are more 
commonly seen in liver disease caused by 
alcohol, such as parotid enlargement, 
Dupuytren’s contracture, and feminization 
in males (31). AH has considerable overlap 
with other liver disease etiologies and they 
share common nonspecific symptoms, such 
as: anorexia, weight loss, abdominal pain, 
abdominal distention, fatigue, nausea, and 
vomiting (21). More advanced liver disease, 
or decompensated AH, may present with 
symptoms, such as jaundice, ascites, spider 
angiomas, fever, and encephalopathy (21).  
 
Laboratory Findings: 
Laboratory findings may give clues to 
alcohol as the underlying etiology. The 
serum AST is commonly 2-6 times the 
upper limit of normal. Further, in 70% of 
patients the AST/ALT ratio is usually 
greater than 2; ratios greater than 3 are even 
more suggestive of AH (10, 32-34).  
 
Imaging & Liver Biopsy:  
To further elucidate the diagnosis of AH, 
imaging studies and liver biopsy can be 
helpful, but are not usually warranted. 
Imaging studies can confirm the presence of 
underlying liver disease, but cannot point to 
a specific etiology (10). Thus, imaging can 
be used to rule out other causes of hepatic 
injury, such as thrombosis or carcinoma. 
Moreover, liver biopsy is useful in 
establishing the diagnosis of AH but is not 
necessary for the management of AH (35). 
Biopsy results vary among AH patients 
depending on the extent and stage of hepatic 
injury determined by alcohol use and 
duration (10). Common pathological 
findings include: steatosis, lobular 
neutrophilic inflammation, periportal 
fibrosis, Mallory bodies (aggregates of 
cytokeratin intermediate filaments), nuclear 
vacuolation, bile duct proliferation, and 
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fibrosis or cirrhosis (36). Luckily, biopsy 
findings may indicate some prognostic 
factors. The severity of inflammation and 
cholestatic changes correlate with 
increasingly poor prognosis and may predict 
response to treatment (37, 38). Further, 
mega-mitochondria seen on biopsy may be 
associated with a milder form of AH, lower 
incidence of cirrhosis, and fewer 
complications with good long-term survival 
(39). Even though pathologic findings may 
provide prognostic value, management and 
treatment of AH is not affected by these 
biopsy results.  
Current recommendations set forth 
by the American Association for the Study 
of Liver Diseases (AASLD) regarding 
diagnosis of AH state that clinicians should 
initially screen patients for alcohol use 
disorders. If an alcohol use disorder is 
identified, the patient should then have 
laboratory testing done to exclude other 
causes of liver injury. Once alcohol has been 
established as the culprit of the hepatic 
injury, patients should then be screened for 
evidence of other end-organ damage. In 
patients where a clinical diagnosis is 
uncertain, or for patients with severe AH 
where medical therapy is being considered, 
a liver biopsy is recommended to further 
clarify the etiology, severity, and prognostic 
factors (10). 
 
PROGNOSTIC ALGORITHMS 
                                                               
Several models are available to predict 
disease severity, survival, and treatment 
response in hepatic injury.  
 
Maddrey’s discriminant function: 
One of the most widely accepted 
models is the Maddrey’s discriminant 
function (MDF) (40). An MDF greater than 
32 has been shown to have a short-term 
mortality around 20-50% at one month (3). 
 
Maddrey’s Discriminant Function: 4.6 * 
(Prothrombin time of patient – 
Prothrombin time of control) + serum 
bilirubin mg/dL 
 
Model for End-Stage Liver Disease: 
Another commonly used scoring 
system is the Model for End-Stage Liver 
Disease (MELD) (13). A MELD score 
greater than 21 has a sensitivity of 75% and 
a specificity of 75% in predicting 90-day 
mortality (41). MELD incorporates 3 widely 
available laboratory variables including the 
international normalized ratio (INR), serum 
creatinine, and serum bilirubin. The original 
mathematical formula for MELD is:  
 
MELD = 9.57 × log (creatinine) + 3.78 × 
Log (total bilirubin) + 11.2 × Log (INR) + 
6.43 
 
The score can be calculated on handheld 
computing devices, and is available at 
www.mayoclinic.org/gi-
rst/mayomodel5.html 
 
Lille model:  
If patients are undergoing treatment 
for AH, the Lille model can be used to guide 
treatment decisions and effectiveness (13, 
42). Based on the Lille score, corticosteroid 
treatment (the mainstay of treatment for AH) 
can be stopped in patients with no 
improvement in Lille score after a week of 
therapy and alternative treatment options 
should be sought (13, 43). 
Lille Score : 3.19 – 0.101 * (age in years) + 
0.147 * (albumin day 0 in g/L) +0.0165 
*(evolution in bilirubin level in M) - 
(0.206 * renal insufficiency) - 0.0065 * 
(bilirubin day 0 in M) -0.0096 * (PT). 
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TREATMENT OF AH 
 
Although AH has been a major problem for 
many decades there have been few advances 
in the treatment of this disease.  
 
Abstinence from alcohol and supportive 
care: 
It has been shown time and time again that 
abstinence from alcohol is the most 
important treatment in patients with AH 
(44). If a patient is willing to undergo 
abstinence from alcohol, a multidisciplinary 
team of hepatologists, psychologists, 
psychiatrists, social workers, and other 
health care team members is highly 
recommended (45).  
In addition, there are many 
medications that can be implemented to help 
patients abstain from alcohol use. A recent 
meta-analysis showed that both, 
acamprosate and oral naltrexone, were 
equally efficacious in reducing the number 
of patients who returned to drinking (46). If 
medications are to be used, the specific 
medication should be tailored to the patient 
based on physician comfort level, side effect 
profile, availability, and cost (46). In 
patients who abstained from alcohol, one 
study found that three-year survival 
approaches 90% and survival was less than 
70% in those who did not abstain (21, 47). 
Once patients have abstained from alcohol, 
if their disease is still active, the MDF 
should be calculated to determine whether 
treatment will be beneficial. If a patient has 
an MDF score of <32 without hepatic 
encephalopathy, or a MELD score of <18, 
then treatment consideration is less urgent 
(10). These patients will likely improve 
spontaneously with abstinence from alcohol 
and supportive care (10). This spontaneous 
improvement is more likely in patients 
whose scores improve during hospitalization 
or who have a decrease in total bilirubin 
level (10).  
Corticosteroids:   
For patients on the opposite end of the 
spectrum with MDF scores that indicate 
treatment (MDF >32), corticosteroids are 
the mainstay of treatment. 
Recommendations set forth by the AASLD 
are to prescribe patients prednisolone (40 
mg/day for 4 weeks then taper over 2-4 
weeks) (10, 48). Although, corticosteroids 
are currently recommended, there is much 
debate about their efficacy and whether side 
effects may outweigh the benefits. A recent 
meta-analysis compared the use of 
glucocorticoids to placebo and found no 
benefit in clinical outcomes for patients on 
prescribed steroids (49). This meta-analysis 
did have high risk of bias and low quality of 
evidence but at the very least it demonstrates 
the controversy surrounding corticosteroid 
use and the need for higher quality studies 
regarding AH treatment (49). Moreover, the 
recent STOPAH Trial showed that 
prednisolone improved 28-day mortality, but 
this did not reach statistical significance, and 
showed no improvement in mortality at 90 
days or 1 year (50). Thus, there is 
conflicting data about whether 
corticosteroids are the most efficacious 
treatment for patients with AH, but it is the 
best option clinicians currently have.  
In addition, it is important to keep in 
mind that patients with AH can have many 
comorbidities associated with alcohol and 
the use of corticosteroids has not been fully 
evaluated in patients with pancreatitis, 
gastrointestinal bleeding, renal failure, or 
active infection (10). In patients with these 
associated comorbidities the risks and 
benefits should be fully explained and 
weighed before treatment is initiated. If 
corticosteroid therapy is initiated, the 
patients’ laboratory markers and Lille Score 
should be closely followed. After seven days 
of therapy, if the Lille score is <0.45 then 
the corticosteroids should be continued for 
the full course (44). However, if the Lille 
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score is >0.45, or if the patient’s bilirubin is 
static or increasing after seven days of 
therapy, the corticosteroids are not 
beneficial and the risks of infection 
outweigh the benefits and alternative 
therapies should be sought (44).  
 
Pentoxifylline:  
Newer experimental treatment options are 
aimed at targeting specific cytokines and 
inflammatory markers involved in the 
pathophysiology of AH. Pentoxifylline, a 
TNF- inhibitor, has been found to lead to a 
reduction in the development of hepatorenal 
syndrome (HRS). A randomized placebo 
controlled clinical trial investigated 
pentoxifylline in 101 hospitalized patients 
with severe AH (51). This study found that 
in-hospital mortality was 40% lower in the 
pentoxifylline arm compared to placebo 
because of a lower likelihood of developing 
HRS leading to death (10, 51). Currently, 
the AASLD guidelines recommend 
pentoxifylline for patients with severe AH 
(MDF >32) and the recommended dose is 
400mg orally 3 times daily for 4 weeks (10). 
This therapy is especially recommended in 
patients in whom steroid therapy is not 
effective or with contraindications to steroid 
use (10, 52).  
Even though pentoxifylline is 
recommended by the AASLD guidelines, 
the STOPAH trial showed that 
pentoxifylline did not improve mortality in 
patients with AH at 28 days, 90 days, or 1 
year. (50). Furthermore, in a select subset of 
patients who do not respond to 
corticosteroids, pentoxifylline has 
traditionally been the alternative treatment. 
However, a recent study by Louvet et al., 
demonstrated that switching to 
pentoxifylline early in the course of 
treatment in patients who do not respond to 
corticosteroids showed no difference in 
mortality outcomes (53). This trial showed 
that in non-responders there was no 
difference in mortality outcomes with 
continuing corticosteroids, discontinuing 
corticosteroids, or switching to 
pentoxifylline early on. (53). There are 
many conflicting studies and 
recommendations regarding the use of 
pentoxifylline, and unfortunately there is no 
clear answer as to its effectiveness. Sadly, 
patients who do not respond to 
corticosteroids are particularly 
disadvantaged because there is no effective 
treatment. 
 
N-acetylcysteine:  
N-acetylcysteine (NAC) has also shown 
benefit in the treatment of AH. A recent 
randomized clinical trial examined the use 
of combination therapy of corticosteroids 
and NAC compared to corticosteroids alone. 
The study found that patients in the NAC 
plus corticosteroid group had improved one-
month survival and had lower rates of 
infection and hepatorenal syndrome; 
however, there was no difference in survival 
at six months (54). While these are 
promising results, larger studies are needed 
before these treatments become standard of 
care. 
 
Liver transplantation:  
The definitive cure for AH is liver 
transplantation. This life-saving intervention 
is reserved for patients when medical 
treatment has failed or is contraindicated 
because of organ scarcity and the increased 
risk of alcohol relapse in this population 
(55). Most liver transplant centers require a 
minimum six months of abstinence before a 
patient can begin the work-up for 
transplantation. The six-month abstinent 
period lacks evidence as a predictor of long-
term sobriety (56). Interestingly, the 
duration of abstinence before undergoing 
transplant does not appear to correlate with 
post-transplant survival. Studies have shown 
that there is not a significant difference 
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between early alcohol use in transplanted 
patients with AH versus non-alcoholic liver 
disease. Sadly, at 7 years post-liver 
transplant, 32% of patients with previous 
AH reported using alcohol (57). 
Unfortunately, data for long term follow-up 
of abstinence in liver transplant patients 
requires further investigation (52). Thus, the 
potentially curative liver transplant is 
reserved for patients in whom medical 
management has failed because of the high 
rate of alcohol relapse and the scarcity of 
donors. 
Recently, there has been a flurry of 
activity surrounding new therapeutic options 
for the management and treatment of AH. 
 
Probiotics: 
Probiotics are an area of interest because 
patients with AH have been shown to have 
increased bacterial overgrowth, intestinal 
mucosal damage, increased gut 
permeability, and associated endotoxemia 
because of this increased permeability (52). 
Certain probiotics have shown decreased 
ALT, AST, lactate dehydrogenase, and 
partial restoration of gut flora (52). 
Furthermore, AH patients have increased 
levels of inflammatory cytokines and 
probiotics have been shown to reduce 
overall inflammatory cytokine burden 
leading to decreased liver disease severity 
and hospitalizations (58, 59). With all of this 
excitement regarding probiotic use, these 
results were from initial studies and much 
more research is needed into these therapies 
before they become mainstream.  
 
 
Stem cell therapy:   
One of the most exciting advancements has 
been in the realm of stem cell therapy. 
Laboratory studies have shown that 
granulocyte colony-stimulating factor (G-
CSF) can mobilize bone marrow stem cells 
to hepatic injury and cause differentiation 
into hepatocytes (60). A small study of 46 
patients with severe AH were randomized to 
receive G-CSF for 5 days with standard 
medical therapy (consisting of pentoxifylline 
with nutrition) vs standard medical therapy. 
Results from the study showed an 
improvement in the patients Child Pugh 
score, MELD, and MDF for up to three 
months (61). While these results are 
promising, larger studies are needed to 
assess the overall efficacy of this treatment 
in AH patients. 
 
Extracorporeal human hepatic cell-based 
liver treatment system: 
One of the most promising advancements is 
the Extracorporeal human hepatic cell-based 
liver treatment system (ELAD). ELAD is 
currently undergoing Phase 3 clinical trials 
and has shown promising results thus far 
(62). Unfortunately, ELAD has only been 
tested in trials with stringent inclusion 
criteria so the available results are not 
generalizable. Moreover, ELAD comes with 
a high cost and requires specially trained 
staff, usually in an intensive care unit.  
Despite potential therapies and 
exciting results, treating AH has remained 
difficult. Even though there is debate over 
the use of corticosteroids and pentoxifylline, 
these medications are currently the first-line 
treatments. 
 
CONCLUSION 
 
Alcoholic hepatitis is an all-to-common 
disease for the hospitalist. The main risk 
factor for development of this disease is 
alcohol use and there is a direct correlation 
between alcohol intake and the development 
of AH. The by-products of alcohol 
metabolism lead directly to hepatocyte 
damage, apoptosis, and activation of 
reparative, inflammatory, and fibrogenic 
processes. Even with the explosion of 
research, there has been little change in the 
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management and treatment of AH. 
Abstinence from alcohol, corticosteroids, 
and proper nutrition are the mainstay of 
treatment for this disease. There are many 
theoretical treatment options on the horizon, 
but unfortunately none have been proven 
more effective thus far. 
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